Equities

Beijing Tiantan Biological Products Corp Ltd

600161:SHH

Beijing Tiantan Biological Products Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)22.80
  • Today's Change0.14 / 0.62%
  • Shares traded32.32m
  • 1 Year change-8.03%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2,8332,1943,317
Total Receivables, Net1331,2011,050
Total Inventory2,8442,3322,144
Prepaid expenses362522
Other current assets, total1,7231,5191,013
Total current assets7,5697,2717,546
Property, plant & equipment, net5,0144,2022,872
Goodwill, net174174128
Intangibles, net1,050930701
Long term investments215218222
Note receivable - long term------
Other long term assets129.219.38
Total assets14,18812,92911,578
LIABILITIES
Accounts payable746973
Accrued expenses989962
Notes payable/short-term debt1192711
Current portion long-term debt/capital leases18124125
Other current liabilities, total970838539
Total current liabilities1,2801,157810
Total long term debt24279384
Total debt161431520
Deferred income tax293120
Minority interest2,9322,5602,215
Other liabilities, total10110697
Total liabilities4,3654,1343,526
SHAREHOLDERS EQUITY
Common stock1,6481,6481,373
Additional paid-in capital2,7932,7933,067
Retained earnings (accumulated deficit)5,3824,3553,612
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.1)(0.1)(0.1)
Total equity9,8238,7958,052
Total liabilities & shareholders' equity14,18812,92911,578
Total common shares outstanding1,9771,9771,977
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.